Dimethyl fumarate (DMF) has been approved for clinical treatment of multiple sclerosis based on its antioxidant and anti-inflammatory effects by activating the Nrf2 pathway. Since both oxidative stress and inflammation are involved in Alzheimer’s disease (AD), DMF is a potential therapeutic option for AD.
Objective:
This study aims to test the therapeutic effects of DMF on AD model mice and to reveal its underlying molecular mechanisms.
Methods:
Cell viability assay and in vitro immunofluorescence imaging were used to evaluate the antioxidant effect of DMF on embryonic mouse hippocampal neurons. Behavioral test and brain magnetic resonance imaging were used to assess the therapeutic effects of DMF on spatial learning and memory as well as hippocampal volume in AD model mice with and without Nrf2 knockdown. Western blotting was used to analyze the expression of antioxidant enzymes and molecules associated with AD-related pathological pathways.
Results:
DMF inhibits reactive oxygen species overproduction and protects neurons without Nrf2 knockdown from death. DMF reduces amyloid-β induced memory impairment and hippocampal atrophy in AD model mice rather than in Nrf2 knockdown AD mice. DMF delays the progression of AD by activating the Nrf2 pathway to enhance the expression of downstream antioxidant enzymes and inhibits lipid peroxidation, apoptosis, inflammation, mitochondrial dysfunction and amyloid-β deposition.
Conclusion:
These results indicate that DMF is a potential therapeutic option for AD through its antioxidant, anti-inflammatory, anti-apoptotic, and other anti-AD effects by activating the Nrf2 pathway.
ScheltensP, BlennowK, BretelerMMB, de StrooperB, FrisoniGB, SallowayS, Van der FlierWM (2016) Alzheimer’s disease. Lancet388, 505–517.
3.
Serrano-PozoA, FroschMP, MasliahE, HymanBT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med1, a006189.
4.
SahooAK, DandapatJ, DashUC, KanharS (2018) Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer’s disease. J Ethnopharmacol215, 42–73.
5.
CheignonC, TomasM, Bonnefont-RousselotD, FallerP, HureauC, CollinF (2018) Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol14, 450–464.
TabnerBJ, El-AgnafOM, TurnbullS, GermanMJ, PaleologouKE, HayashiY, CooperLJ, FullwoodNJ, AllsopD (2005) Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem280, 35789–35792.
14.
SinghA, KukretiR, SasoL, KukretiS (2019) Oxidative stress: A key modulator in neurodegenerative diseases. Molecules24, 1583.
15.
FãoL, MotaSI, RegoAC (2019) Shaping the Nrf2-ARE-relatedpathways in Alzheimer’s and Parkinson’s diseases. Ageing ResRev54, 100942.
16.
MaQ (2013) Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol53, 401–426.
17.
LiuQ, JinZ, XuZ, YangH, LiL, LiG, LiF, GuS, ZongS, ZhouJ, CaoL, WangZ, XiaoW (2019) Antioxidant effects of ginkgolides and bilobalide against cerebral ischemia injury by activating the Akt/Nrf2 pathway in vitro and in vivo. Cell Stress Chaperones24, 441–452.
18.
LuMC, JiJA, JiangZY, YouQD (2016) The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: An update. Med Res Rev36, 924–963.
19.
BellezzaI, GiambancoI, MinelliA, DonatoR (2018) Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res1865, 721–733.
20.
LobodaA, DamulewiczM, PyzaE, JozkowiczA, DulakJ (2016) Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cell Mol Life Sci73, 3221–3247.
21.
AbedDA, GoldsteinM, AlbanyanH, JinH, HuL (2015) Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents. Acta Pharm Sin B5, 285–299.
22.
JiangT, ChengH, SuJ, WangX, WangQ, ChuJ, LiQ (2020) Gastrodin protects against glutamate-induced ferroptosis in HT-22 cells through Nrf2/HO-1 signaling pathway. Toxicol In Vitro62, 104715.
23.
TapiasV, JainuddinS, AhujaM, StackC, ElipenahliC, VignisseJ, GergesM, StarkovaN, XuH, StarkovAA, BettendorffL, HushpulianDM, SmirnovaNA, GazaryanIG, KaideryNA, WakadeS, CalingasanNY, ThomasB, GibsonGE, DumontM, BealMF (2018) Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy. Hum Mol Genet27, 2874–2892.
24.
KerrF, Sofola-AdesakinO, IvanovDK, GatliffJ, Gomez Perez-NievasB, BertrandHC, MartinezP, CallardR, SnoerenI, CocheméHM, AdcottJ, KherichaM, Castillo-QuanJI, WellsG, NobleW, ThorntonJ, PartridgeL (2017) Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer’s disease. PLoS Genet13, e1006593.
25.
AlbrechtP, BouchachiaI, GoebelsN, HenkeN, HofstetterHH, IssbernerA, KovacsZ, LewerenzJ, LisakD, MaherP, MausbergA-K, QuasthoffK, ZimmermannC, HartungH-P, MethnerA (2012) Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation9, 163.
26.
CarlströmKE, EwingE, GranqvistM, GyllenbergA, AeinehbandS, EnokssonSL, ChecaA, BadamTVS, HuangJ, Gomez-CabreroD, GustafssonM, Al NimerF, WheelockCE, KockumI, OlssonT, JagodicM, PiehlF (2019) Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes. Nat Commun10, 3081.
27.
LipsyRJ (2010) Will the newer oral MS agents be welcomed by managed care organizations?Am J Manag Care16, S227–S233.
Abd El-FatahIM, AbdelrazekHMA, IbrahimSM, AbdallahDM, El-AbharHS (2021) Dimethyl fumarate abridged tauo-/amyloidopathy in a D-Galactose/ovariectomy-induced Alzheimer’s-like disease: Modulation of AMPK/SIRT-1, AKT/CREB/BDNF, AKT/GSK-3β, adiponectin/Adipo1R, and NF-κB/IL-1β/ROS trajectories. Neurochem Int148, 105082.
35.
RojoAI, PajaresM, García-YagüeAJ, BuendiaI, Van LeuvenF, YamamotoM, LópezMG, CuadradoA (2018) Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy. Redox Biol18, 173–180.
36.
ScannevinRH, ChollateS, JungM-y, ShackettM, PatelH, BistaP, ZengW, RyanS, YamamotoM, LukashevM (2012) Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther341, 274–284.
37.
WangJ, LiangH, ZhaoY, LiuX, YangK, SuiA (2015) Construction and identification of an RNA interference lentiviral vector targeting the mouse TNF-α gene. Exp Ther Med10, 2283–2288.
38.
MorimotoK, YoshimiK, TonohiroT, YamadaN, OdaT, KanekoI (1998) Co-injection of beta-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons. Neuroscience84, 479–487.
39.
HruskaZ, DohanichGP (2007) The effects of chronic estradiol treatment on working memory deficits induced by combined infusion of beta-amyloid (1-42) and ibotenic acid. Horm Behav52, 297–306.
40.
HuangM, HuM, SongQ, SongH, HuangJ, GuX, WangX, ChenJ, KangT, FengX, JiangD, ZhengG, ChenH, GaoX (2015) GM1-modified lipoprotein-like nanoparticle: Multifunctional nanoplatform for the combination therapy of Alzheimer’s disease. ACS Nano9, 10801–10816.
WangS, LiuC, ChenY, ZhuAD, QianF (2018) Aggregation of hydroxypropyl methylcellulose acetate succinate under its dissolving pH and the impact on drug supersaturation. Mol Pharm15, 4643–4653.
43.
EruslanovE, KusmartsevS (2010) Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol594, 57–72.
44.
HauptmannN, GrimsbyJ, ShihJC, CadenasE (1996) The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch Biochem Biophys335, 295–304.
45.
Di MeoS, ReedTT, VendittiP, VictorVM (2016) Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev2016, 1245049.
46.
BrückJ, DringenR, AmasunoA, Pau-CharlesI, GhoreschiK (2018) A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis. Exp Dermatol27, 611–624.
47.
SawCL, GuoY, YangAY, Paredes-GonzalezX, RamirezC, PungD, KongAN (2014) The berry constituents quercetin, kaempferol, and pterostilbene synergistically attenuate reactive oxygen species: Involvement of the Nrf2-ARE signaling pathway. Food Chem Toxicol72, 303–311.
48.
KeumYS, ChoiBY (2014) Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway. Molecules19, 10074–10089.
49.
ReedTT, PierceWM, MarkesberyWR, ButterfieldDA (2009) Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res1274, 66–76.
50.
ShinSW, KimDH, JeonWK, HanJS (2020) 4-hydroxynonenal immunoreactivity is increased in the frontal cortex of 5XFAD transgenic mice. Biomedicines8, 326.
51.
AndersenJK (2004) Oxidative stress in neurodegeneration: Cause or consequence?Nat Med10 Suppl, S18–25.
52.
SuneethaA, RajaRajeswari K (2016) Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review. J Chromatogr B Analyt Technol Biomed Life Sci1019, 15–20.
53.
BobinskiM, de LeonMJ, WegielJ, DesantiS, ConvitA, Saint LouisLA, RusinekH, WisniewskiHM (2000) The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer’s disease. Neuroscience95, 721–725.
54.
WhitwellJL, DicksonDW, MurrayME, WeigandSD, TosakulwongN, SenjemML, KnopmanDS, BoeveBF, ParisiJE, PetersenRC, JackCRJr., JosephsKA (2012) Neuroimaging correlates of pathologically defined subtypes of Alzheimer’s disease: A case-control study. Lancet Neurol11, 868–877.
55.
SonowalH, RamanaKV (2019) 4-hydroxy-trans-2-nonenal in the regulation of anti-oxidative and pro-inflammatory signaling pathways. Oxid Med Cell Longev2019, 5937326.
56.
ZarkovicK (2003) 4-hydroxynonenal and neurodegenerative diseases. Mol Aspects Med24, 293–303.
WangJ, FieldsJ, ZhaoC, LangerJ, ThimmulappaRK, KenslerTW, YamamotoM, BiswalS, DoréS (2007) Role of Nrf2 in protection against intracerebral hemorrhage injury in mice. Free Radic Biol Med43, 408–414.
59.
UttaraB, SinghAV, ZamboniP, MahajanRT (2009) Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol7, 65–74.
60.
RadiE, FormichiP, BattistiC, FedericoA (2014) Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis42 Suppl 3, S125–152.
61.
CaiL, WangH, LiQ, QianY, YaoW (2008) Salidroside inhibits H2O2-induced apoptosis in PC12 cells by preventing cytochrome c release and inactivating of caspase cascade. Acta Biochim Biophys Sin40, 796–802.
62.
MarchenkoND, ZaikaA, MollUM (2000) Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem275, 16202–16212.
63.
FischerR, MaierO (2015) Interrelation of oxidative stress and inflammation in neurodegenerative disease: Role of TNF. Oxid Med Cell Longev2015, 610813.
64.
MontgomerySL, BowersWJ (2012) Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol7, 42–59.
65.
CadonicC, SabbirMG, AlbensiBC (2016) Mechanisms of mitochondrial dysfunction in Alzheimer’s disease. Mol Neurobiol53, 6078–6090.
